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Abstract
 
A characteristic of the three human-pathogenic 
 
Yersinia
 
 spp. (the plague agent 
 
Yersinia pestis
 
 and
the enteropathogenic 
 
Yersinia pseudotuberculosis
 
 and 
 
Yersinia enterocolitica
 
) is the expression of the
virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced
secretion of yersinia antihost proteins and in evasion of the host’s innate immune response.
 
Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-
dependent fashion leading to immunosuppression by interleukin 10 induction. The impact of
this immunosuppressive effect for yersinia pathogenesis is underlined by the observation that
TLR2-deficient mice are less susceptible to oral 
 
Y. enterocolitica
 
 infection than isogenic wild-
type animals. In summary, these data demonstrate a new ligand specificity of TLR2, as LcrV is
the first known secreted and nonlipidated virulence-associated protein of a Gram-negative bac-
terium using TLR2 for cell activation. We conclude that yersiniae might exploit host innate
pattern recognition molecules and defense mechanisms to evade the host immune response.
Key words: immunity • monocytes/macrophages • inﬂammation • bacterial proteins • 
immunosuppression
 
Introduction
 
Yersinia pestis
 
, the etiologic agent of plague, and the entero-
pathogenic species 
 
Yersinia pseudotuberculosis
 
 and 
 
Yersinia en-
terocolitica
 
 have a 70-kb conserved virulence plasmid (pYV)
in common which enables these obligate extracellular
Gram-negative bacteria to resist the immune system of
their host (1). It encodes several virulence-associated com-
ponents including a type III protein secretion and translo-
 
cation system (TTS),
 
*
 
 the surface exposed adhesin YadA,
anti-host effector proteins, which are probably injected by
a needle-like mechanism into the cytosol of target cells (2),
and proteins which are released into the environment (1,
3). The function of several Yops have been elucidated, e.g.,
YopH impairs focal adhesion complexes by its protein ty-
rosine phosphatase activity, YopE and YopT inactivate the
small GTPases Rac and Rho, respectively, and YopP/YopJ
blocks activation of nuclear factor (NF)-
 
 
 
B and mitogen-
activated protein (MAP) kinases (1, 3). The concerted ac-
 
tion of injected Yops results in paralysis of those professional
phagocytes which have contacted yersinae bacilli (“para-
lytical kiss”).
The virulence- (V-) antigen is a released multifunctional
protein (4, 5). It was originally described as the major viru-
lence marker of 
 
Y. pestis
 
 (6). Later, it was shown that the
V-antigen (denoted as LcrV) is encoded by pYV and is ex-
pressed and released into the environment by all human
pathogenic 
 
Yersinia
 
 species. It is required for regulation of
Yop production and, together with YopB and YopD, for
polarized translocation of Yops into host cells; furthermore,
LcrV is capable to form channels in artificial bilayer mem-
branes (7, 8). Additionally, LcrV exhibits immunomodula-
tory features: treatment of mice with 
 
r
 
LcrV results in sup-
pression of TNF-
 
 
 
 and IFN-
 
 
 
 and amplification of IL-10
in spleen homogenates (9, 10). There is a large body of ev-
idence that LcrV has also a protective capacity as vaccine,
probably because antibodies against LcrV result in neutral-
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ization of the immunosuppressive effect and/or inhibition
of Yop translocation (9, 11, 12). Recently, we could
demonstrate that 
 
r
 
LcrV treatment of murine toll-like recep-
tor 4 (TLR4)-defective C3H/HeJ macrophages and human
MonoMac6 monocytic cells leads to TNF-
 
 
 
 suppression
via IL-10 induction in a dose-dependent manner (range of
activity: 50 ng/ml to 5 
 
 
 
g/ml, corresponding to 1.35 to
135 nM; 13). Boiling of LcrV, digestion with proteinase K,
and use of anti-LcrV antibodies completely abolished the
immunomodulating capacity of LcrV. Strikingly, 
 
r
 
LcrV-
treated proteose-peptone elicited macrophages (PPMs)
from IL-10-deficient (IL-10
 
 
 
/
 
 
 
) mice exhibit no TNF-
 
 
 
suppression upon subsequent zymosan A stimulation. Inter-
estingly, despite sharing several features with LcrV (8, 14),
the LcrV-homologue protein of 
 
Pseudomonas aeruginosa
 
,
PcrV, elicits no comparable immunosuppressive capacity
(13). The signaling pathway leading to IL-10 production
by LcrV is unknown. Due to its resemblance with the ef-
fects of endotoxin (LPS) tolerance we wondered whether
LPS and LcrV might share common signaling pathways.
 
Materials and Methods
 
Mice.
 
CD14
 
 
 
/
 
 
 
 and C57/BL6 mice were purchased from
The Jackson Laboratory. Mice deficient in TLR2 generated by
gene targeting as described previously (15) were provided by Tu-
larik Inc. All mice were bred under specific pathogen-free condi-
tions. Female mice were used at 6–8 wk of age.
 
Materials. r
 
LcrV and 
 
r
 
PcrV were produced as described pre-
viously (13). The molecular mass of 
 
r
 
LcrV (39.661 kD) was
confirmed by mass spectrometry using matrix-assisted laser
desorption-ionization mass spectrometry (MALDI-MS) analysis
(Toplab). Thus, a putative protein modification, e.g., acetylation
or lipidation, could be excluded. Moreover, 
 
r
 
LcrV was found to
be LPS-free as measured by limulus amebocyte assay (Pyroquant).
Peptides were provided by Dieter Palm, Physiologische Chemie
I, Würzburg, Germany.
 
Preparation and Stimulation of Murine Peritoneal Macrophages In
Vitro.
 
PPMs were prepared as described previously (13). Briefly,
10
 
6
 
 cells/ml were treated for 2 h with 5 
 
 
 
g/ml 
 
r
 
LcrV. Superna-
tants were collected for IL-10 measurements by ELISA.
 
Transfections.
 
Cells of a subclone of the human embryonic
kidney (HEK) 293 cell line (Tularik Inc.) were transfected with
DNA constructs for CD14, TLR 1, TLR 2, TLR 4, endothelial
cell-leukocyte adhesion molecule (ELAM-1) luciferase, and Rous
sarcoma virus (RSV-)-
 
 
 
-galactosidase as described previously
(16). The DNA constructs for TLR1, TLR2, and TLR4 were
FLAG-epitope-tagged as described (16). MD2 plasmid was a kind
gift from Kensuke Miyake, University of Tokyo, Japan. Trans-
fected cells were stimulated for 6 h with 
 
r
 
LcrV in the presence or
absence of 10 
 
 
 
g/ml polymyxin B (Sigma-Aldrich). To rule out
any bacterial contaminant known so far to signal via CD14/
TLR2 to be present in our 
 
r
 
LcrV preparation, 
 
r
 
LcrV was boiled
for 1 h before use to serve as negative control. After 
 
r
 
LcrV-treat-
ment cells were lysed for measurement of luciferase activity using
reagents from Boehringer. Luciferase activity was measured in a
darkbox with a microtiter plate chemiluminometer (Hamamatsu
Phototonics). An RSV-
 
 
 
-galactosidase control plasmid was used
for normalizing transfection efficiencies.
 
MonoMac-6 Cell Procedures.
 
Cells of the human monocytic
cell line MonoMac-6 grown in RPMI 1640 supplemented with
 
10% FCS for 3 d at a cell density of 2 
 
 
 
 10
 
5
 
 cells/ml were used
for experiments testing responsiveness to LcrV as described previ-
ously (13). After 18 h of pretreatment with 5 
 
 
 
g/ml 
 
r
 
LcrV, cells
were stimulated with 1 mg/ml zymosan A (Sigma-Aldrich). 6 h
later supernatants were collected for measurement of TNF-
 
 
 
 lev-
els. To evaluate the influence of CD14 on the immunomodulat-
ing effect of 
 
r
 
LcrV, MonoMac-6 cells were preincubated for 1 h
before 
 
r
 
LcrV-treatment with monoclonal anti-CD14 antibodies
bIG 10 (biometec) or MEM-18 (a kind gift from Dr. Václav
Horej í, Institute of Molecular Genetics, Praha, Czech Repub-
lic) which inhibit LPS-binding to CD14. As control served the
corresponding isotype anti-CD14 mAbs bIG 4 and MEM-15
which do not block LPS effects. mAb concentrations of 10 
 
 
 
g/
ml were used.
 
Assays for TNF-
 
 
 
 and IL-10.
 
TNF-
 
 
 
 and IL-10 levels were
measured by commercially available ELISAs as described previ-
ously (13).
 
Coating of rLcrV and rPcvV to Latex Beads.
 
Non-covalent
coating of latex beads (4-
 
 
 
m diameter beads, sulfate micro-
spheres; Molecular Probes) with 
 
r
 
LcrV and 
 
r
 
PcrV was performed
as described (17). Briefly, purified recombinant proteins were di-
alyzed against PBS, pH 7.0. Approximately 10
 
9
 
 latex beads were
washed with 1 ml of PBS and resuspended in 500 
 
 
 
l of PBS. Re-
combinant LcrV and PcrV (1 mg) were coincubated with the la-
tex beads for 3 h at room temperature to allow absorption to the
beads. After adding 500 
 
 
 
l of 20 mg/ml BSA, the solution was
incubated at room temperature for 1 h. Subsequently, beads were
washed with PBS containing 1 mg/ml BSA and stored at 4
 
 
 
C in
500 
 
 
 
l of PBS containing 0.2 mg/ml BSA. The coupling effi-
ciency was tested by immunofluorescence staining of the coated
beads with specific anti-
 
r
 
LcrV and anti-
 
r
 
PcrV antibodies, respec-
tively, and a FITC-labeled secondary goat anti-rabbit antibody
(Molecular Probes; unpublished data).
 
Immunofluorescence Procedures.
 
Immunofluorescence staining
was performed as described previously (17). Briefly, cells were
washed three times with serum-free medium. Latex beads coated
with 
 
r
 
LcrV or 
 
r
 
PcrV were centrifuged onto the cells (800 r.p.m.,
3 min, 4
 
 
 
C). After an incubation period of 30 min at 37
 
 
 
C in a
humidified atmosphere of 5% CO
 
2
 
, cells were fixed with 3.7%
formaldehyde (Sigma-Aldrich) and permeabilized with 0.1% tri-
ton-PBS (Sigma-Aldrich). Before staining, cells were blocked
with 10% human serum. For staining, polyclonal rabbit anti-
murine TLR2 (from a purified polyclonal rabbit antiserum
raised against a 28-mer peptide H
 
2
 
N-FNPSESDVVSELGKVE-
TVTIRRLHIPQC-CONH
 
2
 
 representing a portion of the
mouse TLR2 extracellular domain, purchased from Eurogentec
Inc.; the antibodies were found not to stain TLR2
 
 
 
/
 
 
 
 PPMs) or
polyclonal rabbit anti-FLAG (Sigma-Aldrich) were used as pri-
mary antibodies, while Alexa 568- or 350-labeled goat anti–rab-
bit antibodies or donkey anti–goat (Molecular Probes) served as
secondary antibodies. Fluorescence was evaluated using a confo-
cal laser microscope.
 
Experimental Infection of Mice. Y. enterocolitica 
 
O8 strain WA-
314 was grown in Luria-Bertani medium at 27
 
 
 
C overnight, sed-
imented, resuspended in 20% glycerol, and frozen at 
 
 
 
80
 
 
 
C. For
infection of mice, aliquots of glycerol-stock cultures were
thawed, washed in sterile PBS (pH 7.4), and diluted to the appro-
priate bacterial concentrations (13). Mice were orally infected
with 5 
 
 
 
 10
 
7
 
 CFU after fasting for 4 h. Mice were killed after 5 d
of oral infection.
 
Determination of the Number of Yersiniae in Spleen and Liver.
 
Spleens and livers were dissected and homogenized as described
previously (13). Yersiniae CFU were determined by plating serial
s ˇ 
1019
 
Sing et al.
 
dilutions on Yersinia selective agar (CIN agar; Becton Dickinson)
and counting the CFU after an incubation period of 40 h at
27
 
 
 
C.
 
Statistical Analysis.
 
In vitro experiments were performed at
least five times. Results are presented as means 
 
 
 
 SD. Animal ex-
periments were performed at least twice using 5–10 animals per
group. Statistical analysis was performed using Student’s two-
sided 
 
t
 
 test. Differences were considered statistically significant at
P values 
 
 
 
 0.05.
 
Results
 
CD14 Is Required for LcrV-induced Immunomodulation.
 
Initially, we investigated whether CD14, the accessory sur-
face protein of TLR4-mediated LPS-signaling (18), is re-
quired for LcrV-induced IL-10 production. PPMs from
CD14
 
 
 
/
 
 
 
 and isogenic CD14
 
 
 
/
 
 
 
 mice were treated with
 
r
 
LcrV for 2 h. Then IL-10 was determined in the culture
supernatant. In contrast to wild-type PPMs, CD14
 
 
 
/
 
 
 
macrophages did virtually not respond with IL-10 produc-
tion (Fig. 1 A). This result showing CD14 dependency of
LcrV-induced immunomodulation was confirmed with the
human macrophage cell line MonoMac-6 using CD14-
blocking antibodies: 
 
r
 
LcrV-mediated suppression of TNF-
 
 
 
could be abrogated by pretreatment of MonoMac-6 with
monoclonal anti-CD14-blocking antibodies bIG10 or
MEM18, but not with anti-CD14-nonblocking antibodies
blG4 or MEM15, respectively (Fig. 1 B). Taken together,
these results indicate that CD14 is required for LcrV-
caused IL-10–mediated TNF-
 
 
 
 suppression.
 
LcrV Signals in a CD14/TLR2-dependent Manner.
 
The
innate immune system orchestrates the inflammatory re-
sponse to pathogens by receptors recognizing microbial
molecules (19). The activation of members of the mamma-
lian TLR family, which are homologous to the Toll system
of 
 
Drosophila
 
, by microbial products triggers intracellular
signaling pathways finally leading to the transcription of
genes relevant for the immune response (20–23). As previ-
ous data using C3H/HeJ PPMs defective in 
 
tlr4 (24)
showed no requirement for TLR4 in LcrV-induced immu-
nomodulation (13), we asked if a different TLR might be
involved in LcrV signaling. We transfected HEK 293 cells
with FLAG-tagged TLR1, TLR2, and TLR4/MD2, re-
spectively, either in the presence or absence of cotrans-
fected CD14 and tested for the ability to respond to rLcrV
in an NF- B–dependent ELAM-1 promoter luciferase re-
porter gene assay (16). Transfected cells expressing CD14,
TLR1, TLR2, or TLR4/MD2 alone did not respond to
LcrV treatment (Fig. 2 A). However, reporter gene activa-
tion was seen in HEK 293 cells cotransfected with CD14
and TLR2, but not with any of the other TLRs mentioned
indicating that LcrV signaling requires CD14/TLR2 com-
plex. Moreover, treatment with polymyxin B (pB), a po-
tent LPS inhibitor, did not influence LcrV signaling via
CD14/TLR2 (Fig. 2 B). In contrast, boiling of our LcrV
preparation which does not impair TLR2-activating bacte-
rial components known so far (including lipopeptides, pep-
tidoglycan, carbohydrates, and LPS) completely abolished
LcrV-signaling via CD14/TLR2 (Fig. 2 B). This finding of
a requirement for CD14 in transfection experiments is also
consistent with the reported results using murine CD14 / 
macrophages and human MonoMac-6 cells
Synthetic Peptides Derived from LcrV Are Capable to Signal
via TLR2 and CD14. Next, we were interested to local-
ize the stimulatory region of LcrV responsible for CD14/
TLR2 signaling. We found that rLcrV constructs (25) lack-
ing different amino acid (aa) regions in the COOH termi-
nus of the protein (aa190–278) and rLcrV constructs com-
prising the first 130 and 100 NH2-terminal aa (rV130 and
rV100) were similarly active as rLcrV regarding their capac-
ity to induce IL-10–mediated TNF-  suppression in C3H/
HeJ PPMs or MonoMac-6 cells and to signal via CD14/
TLR2 (unpublished data). Therefore, we concluded that
the COOH-terminal region comprising aa101-aa334 is
not needed for IL-10–mediated immunosuppression and
CD14/TLR2-dependent signaling. In a next approach,
overlapping synthetic peptides of 36 and 37 aa in size cov-
ering stepwise the NH2 terminus of LcrV (V1: aa2–aa39,
Figure 1. CD14 is required for LcrV-induced immunomodulation. (A)
IL-10 induction by rLcrV is virtually absent in CD14  /  PPMs. PPMs
were treated for 2 h with 5  g/ml rLcrV (white bars) or left untreated
(black bars). IL-10 was measured in the supernatants by ELISA. *P  
0.001. (B) rLcrV-induced immunomodulation is CD14-dependent in
MonoMac-6 cells. MonoMac-6 cells were treated for 1 h with monoclo-
nal anti-CD14 blocking antibodies bIG 10 and MEM-18 or the corre-
sponding isotype nonblocking anti-CD14 mAbs bIG 4 and MEM-15
before 18 h stimulation with rLcrV (5  g/ml) or LPS (1 ng/ml), respec-
tively. TNF-  production upon stimulation with zymosan A (1 mg/ml)
for 6 h was determined in the cell supernatants by ELISA.1020 Yersinia LcrV Exploits TLR2/CD14 for IL-10–mediated Immunosuppression
V2: aa31–aa70, V3: aa60–aa98, and V4: aa94–aa131) were
generated and tested in CD14/TLR2-cotransfected HEK
293 cells indicating that the active region of LcrV was pre-
sumably located between aa 31 and aa70 (unpublished
data). By comparing the aa sequence of LcrV with that of
PcrV, which had been found to be unable to cause TNF- 
suppression via IL-10 induction in murine and human
macrophages (13), a gap in the aa sequence of PcrV was
recognized corresponding to aa41 to aa59 of LcrV (Fig. 2
C). Thus, we designed three synthetic polypeptides derived
from LcrV aa sequence: V5: aa27 – aa43, V7: aa31 – aa49,
and V9: aa39-aa57. In CD14/TLR2 cotransfected HEK
293 cells, peptide V7 (10  g/ml) induced luciferase activity
in our reporter assay to a similar degree as rLcrV (5  g/ml),
whereas treatment with peptide V5 (10  g/ml) or the
pseudomonas homologue rPcrV (5  g/ml) were not stim-
ulating (Fig. 2 B). Peptide V9 (10  g/ml) was less active
than V7. These results demonstrate that a synthetic oli-
gopeptide derived from the NH2-terminal region of LcrV
is capable to induce CD14/TLR2 signaling.
TLR2 Colocalizes with LcrV, but Not with PcrV. Re-
cently, it was shown that TLR2 accumulation at the mac-
rophage membrane–zymosan particle contact site and
phagocytosis precede zymosan-mediated TLR2 signaling
(26). Therefore, we wondered whether latex beads coated
with rLcrV could show similar characteristics as zymosan
particles with respect to TLR2 recruitment. Latex beads of
4  m in diameter were coated with rLcrV (LcrV-beads)
and rPcrV (PcrV-beads), respectively, and incubated with
wild-type PPMs. Immunofluorescence-staining with anti-
TLR2 antibodies revealed the enrichment of TLR2
around rLcrV-, but not around rPcrV-coated particles in
so-called “phagocytic cups” (Fig. 3). Corresponding results
were obtained with LcrV- and PcrV-beads in FLAG-
tagged TLR2 transfected HEK 293 cells (unpublished
data). Thus, these results support the hypothesis that LcrV,
but not PcrV is capable to induce signaling by interaction
with TLR2 and suggest that both murine and human
TLR2 discriminate between the closely related proteins
rLcrV and rPcrV.
TLR2 Is Involved in LcrV-induced Immunomodulation and Is
Required for Susceptibility to Y. enterocolitica Infection. Fur-
ther evidence for recognition of LcrV by TLR2 eventually
leading to IL-10 induction was obtained by comparison of
PPMs from TLR2 /  and congenic TLR2 /  mice of
SV129xB57BL/6 (denoted SV129) or C57/BL6 back-
ground, respectively. rLcrV-treatment of PPMs derived
from the respective wild-type mice resulted in a markedly
enhanced IL-10 response when compared with PPMs from
the corresponding TLR2 /  mice (Fig. 4 A). Based on
previous data showing that IL-10 /  mice are highly resis-
tant to yersiniae infection (13) and assuming that LcrV-
mediated immunosuppression via IL-10 which is transmit-
ted in a CD14/TLR2-dependent manner could play an
important role in yersinae infection we speculated that
TLR2 /  mice might be less susceptible to an oral chal-
lenge with the enteropathogenic Y. enterocolitica strain WA-
314. 5 d after oral inoculation with 5   107 CFU Y. entero-
colitica, bacterial counts in spleen and liver of TLR2 / 
SV129xB57BL/6 and TLR2 /  C57/BL6 mice were
Figure 2. LcrV signals in a CD14/TLR2-dependent
manner. (A) CD14/TLR2-cotransfected HEK 293 cells
respond to rLcrV. HEK 293 cells were transiently cotrans-
fected with plasmids encoding an ELAM-1 luciferase re-
porter, a  -galactosidase gene (for normalizing transfection
efficiencies) and the indicated TLRs (plus MD2 where de-
picted) or an empty vector plasmid without or with a
CD14 plasmid for 24 h. Cells were left untreated (black
bars) or stimulated with 5  g/ml rLcrV (white bars). After
6 h luciferase activities were determined. (B) A synthetic
oligopeptide derived from the NH2-terminal region of
LcrV is capable to induce CD14/TLR2 signaling. CD14-
TLR2 cotransfected HEK 293 cells were stimulated with
the peptides V7, V9, and V5 (10  g/ml), rLcrV (5, 1, and 0.5  g/ml) and rPcrV (5  g/ml), respectively, or left untreated. Addition of polymyxin B
( pB; 10  g/ml) and boiling of LcrV for 1 h before stimulation served as controls. After 6 h luciferase activities were determined. (C) Amino acid se-
quences of the NH2-terminal region of PcrV (aa1-aa39), LcrV (aa1-aa56), and the synthetic polypeptides V5, V7, and V9.1021 Sing et al.
about two logs lower than those in the respective organs of
congenic TLR2 /  mice (Fig. 4 B).
Discussion
In this study we focused on the signaling of V antigen–
induced innate immunity responses. For the first time we
demonstrate that a bacterial nonlipidated protein associated
with virulence and derived synthetic oligopeptides are ca-
pable to induce IL-10 production via TLR2/CD14 signal-
ing. In contrast to the pseudomonas rPcrV, rLcrV (range of
activity: 10–100 nM) transmits signaling via TLR2 in a
CD14-dependent manner leading to IL-10 induction
which finally causes TNF-  suppression thus probably en-
abling yersiniae to evade the host innate immune system.
Several lines of evidence obtained in vitro both in murine
and human cell systems support this conclusion: (a) Only
CD14-TLR2-cotransfected HEK 293 cells, but not cells
transfected with TLR2 alone responded with NF- B–
dependent ELAM-1 promoter luciferase activity upon
rLcrV stimulation. (b) Blocking anti-CD14 monoclonal
antibodies, but not nonblocking isotype anti-CD14 anti-
bodies completely abolished TNF-  suppression in LcrV-
treated MonoMac-6 cells suggesting that CD14 is needed
for recognition of V antigen and transmission of V anti-
gen-caused cellular effects. (c) In contrast to wild-type or
TLR4-deficient (13) murine macrophages of different ge-
netic backgrounds, CD14- as well as TLR2-deficient
PPMs of different genetic backgrounds do not respond to
rLcrV by IL-10 induction. (d) Colocalization of rLcrV, but
not rPcrV with TLR2 was visualized both in murine PPMs
and TLR2-transfected human HEK 293 cells; the enrich-
ment of TLR2 around rLcrV-, but not around rPcrV-
coated particles in so-called “phagocytic cups” suggests that
both murine and human TLR2 discriminate between the
closely related proteins LcrV and PcrV.
Previously we could clearly attribute TNF-  suppres-
sion and IL-10 induction to the protein component of our
rLcrV preparation (13), as denaturation by boiling or pro-
teinase K degradation completely abolished the observed
immunomodulation. Moreover, antibodies against rLcrV
greatly impaired LcrV-induced immunomodulating effects
(13). In the present study we chose further strategies to
rule out an involvement of contaminants possibly present
in our rLcrV preparation in CD14-TLR2–dependent sig-
naling by rLcrV: (a) addition of polymyxin B to LcrV-
treated cotransfected cells which did not influence CD14-
TLR2–dependent signaling, (b) boiling of rLcrV before
use which completely abrogated CD14-TLR2–dependent
signaling, (c) comparison of rLcrV-signaling with that of
the similarly produced rPcrV which is not able to signal
via CD14/TLR2, and (d) the successful use of synthetic
peptides. Finally, we could exclude rLcrV modification by
MALDI-MS analysis. All these approaches indicate that
any bacterial contaminants known so far to use TLR2 for
signaling are unlikely to be responsible for CD14-TLR2–
dependent signaling by rLcrV. Moreover, the active re-
gion of LcrV for CD14-TLR2-mediated recognition
Figure 3. TLR2 colocalizes
with LcrV, but not with PcrV.
TLR2 is enriched around rLcrV-
but not rPcrV-coated latex beads
in murine PPMs. Murine
TLR2 /  PPMs were incubated
with latex beads coated with
rLcrV or rPcrV. After fixation,
permeabilization and blocking
cells were stained with poly-
clonal anti–mouse TLR2 anti-
bodies and a second immunoflu-
orescent antibody. White arrows
indicate enrichment of TLR2
around LcrV beads.1022 Yersinia LcrV Exploits TLR2/CD14 for IL-10–mediated Immunosuppression
could be located to the first 100 NH2-terminal aa of LcrV,
since truncated constructs of LcrV carrying different dele-
tions in the region of aa190–278 (25) or lacking two thirds
of the COOH-terminal region of LcrV (rV130 and
rV100) exhibited similar TNF-  suppressive effects in
MonoMac-6 cells and a NF-kB–inducing capacity in
CD14/TLR2-cotransfected HEK 293 cells as rLcrV. Fur-
thermore, we could define an active region of LcrV which
comprises aa31–49 using different synthetic peptides de-
rived from LcrV aa-sequence. Interestingly, a protective
antigenic region located between aa 2 and 135 of V-anti-
gen had previously been identified besides a protective an-
tigenic region between aa 135 and 275 by vaccination ex-
periments (27).
In summary, our data clearly demonstrate a new ligand
specificity of TLR2. In striking contrast to all bacterial com-
ponents known so far to signal via TLR2, LcrV is a chemi-
cally nonmodified bacterial virulence-associated protein.
The TLR2 dependency of rLcrV-induced IL-10 pro-
duction raised the question whether TLR2 contributes to
susceptibility of mice to yersinia infection. In striking con-
trast to a protective role of TLR2 in Borrelia burgdorferi (28)
and Staphylococcus aureus (29) infected mice, however, the
absence of TLR2 renders mice more resistant to an oral Y.
enterocolitica infection. The strategy of yersiniae to exploit
an innate immunity effector, i.e., host macrophage-derived
IL-10, might therefore be connected to the use of a host
pattern recognition receptor (PRR), TLR2, to evade the
host immune response. As TLR2-deficient PPMs show a
greatly impaired IL-10 production upon LcrV stimulation,
one might speculate that LcrV is a key player in this novel
pathogenicity mechanism by which yersiniae exploit a host
PRR for subverting the host immune system. Unfortu-
nately, this key role of LcrV cannot be demonstrated by
simple insertional inactivation of the encoding gene lcrV,
because this leads to impairment of the TTS and conver-
sion to avirulence of yersiniae (1). Therefore, sophisticated
site-directed mutagenesis of the NH2-terminal encoding
region of the lcrV gene by maintaining the TTS function
would be required.
Figure 4. TLR2 is involved in LcrV-induced immunomodulation and is required for susceptibility to Y. enterocolitica infection. (A) LcrV-induced IL-10
production is highly impaired in TLR2-deficient PPMs. PPMs of different TLR2-deficient and corresponding wild-type mice (SV129xB57BL/6 and
C57BL/6 background) were treated with rLcrV (5  g/ml) for 2 h (white bars) or left untreated (black bars). IL-10 was measured in the supernatant by
ELISA. *P   0.001. (B) TLR2-deficient mice are highly resistant to oral Y. enterocolitica infection. TLR2 /  (black bars) and corresponding wild-type
(white bars) mice of the indicated genetic backgrounds were orally infected with 5   107 CFU Y. enterocolitica O8. After 5 d the number of yersiniae in
spleen and liver was determined. Data represent results obtained by using 5–10 mice in at least two independent experiments (P values   0.05).1023 Sing et al.
Mammals are endowed with a large set of PRRs for sur-
veillance of microbial invaders and for immediate immune
response. This system is efficient for defense of apathogenic
and probably of facultative pathogenic microbes (“immune
homeostasis”). Presumably apathogenic invaders elicit a
short-lived inflammatory response followed by IL-10–mediated
down-regulation which is sufficient for elimination of
harmless microbes. However, a characteristic feature of
pathogenic microbes is the capability to break through the
first line of defense represented by innate immunity. Thus,
IL-10–mediated down-regulation of the innate immunore-
sponse can be harmful for the host infected with patho-
genic microbes, in particular with yersiniae, which have
developed a short distance anti-host weapon mediated by
the TTS/Yop system and a long distance weapon mediated
by the released LcrV bacteriokine (30).
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